Mylan promised again Thursday to stop referring to its 2018 earnings target in connection with its hostile bid for Irish drug maker Perrigo.

The renewed pledge was made because, days after the company made the same promise to Irish regulators last month, CEO Heather Bresch referred to the earnings goal in a presentation to investors.

Mylan said Thursday that Irish officials had asked the generic drug maker to issue the clarification and retraction.

Mylan reincorporated in the Netherlands earlier this year to lower its global tax bill, but maintains its operational headquarters in Cecil.

Advertise with us

The company has made no secret that it wants to grow adjusted earnings to at least $6 per share by 2018. Perrigo, which is opposing Mylan’s cash-and-stock bid, objected to Mylan using the figure, saying it should be treated as a forecast under Irish takeover rules.

On May 27, Mylan issued a statement saying that although the $6 figure was a target, not a forecast, the company would refrain from referring to it.

Two days later, Ms. Bresch spoke to investors at a conference in New York sponsored by Sanford Bernstein. A transcript of her presentation indicates she cited the target in answering a question from an industry analyst.

In a statement Thursday, Mylan said “a representative of Mylan inadvertently” referred to the target at a May 29 investor conference. Irish officials “asked Mylan to issue this announcement withdrawing the 2018 target ... and to reiterate that it will no longer during the offer period refer to that 2018 target,” the company stated.

Mylan plans to hold a shareholder meeting early in the third quarter seeking approval to acquire Perrigo, an over-the-counter generic drug maker.

Advertise with us

Separately, European Union antitrust regulators on Thursday set a provisional deadline of July 29 for ruling on the proposed acquisition.

Many believe Mylan’s bid for Perrigo is an effort to thwart a hostile, $40 billion bid for Mylan made by Israel generic drug maker Teva Pharmaceutical Industries. Teva has acquired a 4.6 percent stake in Mylan, a big enough stake to challenge the company’s takeover defense in Dutch courts.

Len Boselovic: lboselovic@post-gazette.com or 412-263-1941.